Biotechnology News and Research

RSS

UMDNJ, Proteonomix commence screening of patients with ESLD for use in UMK-121 clinical trial

PROTEONOMIX, INC., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company has commenced the screening of patients with End Stage Liver Disease (ESLD) for use in its clinical trial of UMK-121.

21 Nov 2012

Novel technology can lead to more efficient and cheaper therapy for Pompe disease

VIB researchers from UGent and Vrije Universiteit Brussel , together with a team of the firm Oxyrane have developed a new technology that can lead to a more efficient and possibly also cheaper therapy for diseases such as Pompe disease. Oxyrane will now start developing a clinical program for this therapy in Pompe disease.

21 Nov 2012

Emory University, Georgia Tech to establish Malaria Host-Pathogen Interaction Center

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded a five-year contract of up to $19.4 million, depending on contract options exercised, to establish the Malaria Host-Pathogen Interaction Center (MaHPIC).

20 Nov 2012

Patheon to launch $30 million transferable rights offering

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced that it will launch a U.S. $30 million transferable rights offering.

19 Nov 2012

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, today announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM).

19 Nov 2012

HORIBA Europe opens new R&D facility

HORIBA Europe has inaugurated its new research and technology center at the Saclay Technopole. Atsushi Horiba, President of the HORIBA Group, cut the ribbon opening the doors to HORIBA’s home for scientific innovation and cooperation.

19 Nov 2012

GVK Biosciences receives AERB approvals to carry out 3H and 14C synthesis activities

GVK Biosciences, Asia's leading Drug Discovery Research & Development organization, has received approvals from the Atomic Energy Regulatory Board (AERB), Government of India, to carry out 3H and 14C synthesis activities.

19 Nov 2012

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Genentech, a member of the Roche Group, today announced results from the positive Phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo>th Annual Meeting of the Society for Neuro-Oncology in Washington, D.C.

19 Nov 2012

Massimo CEO wins Ernst & Young Entrepreneur Of The Year Award

Joe Kiani, founder, CEO and Chairman of the Board of Massimo Corporation, has been named the Ernst & Young National Entrepreneur Of The Year 2012 Life Sciences Award Winner.

19 Nov 2012

New nanoparticle halts relapsing remitting multiple sclerosis in mouse model

In a breakthrough for nanotechnology and multiple sclerosis, a biodegradable nanoparticle turns out to be the perfect vehicle to stealthily deliver an antigen that tricks the immune system into stopping its attack on myelin and halt a model of relapsing remitting multiple sclerosis (MS) in mice, according to new Northwestern Medicine research.

19 Nov 2012

NIH-funded scientists develop new treatment to combat autoimmune disorders in mouse model

In a mouse model of multiple sclerosis (MS), researchers funded by the National Institutes of Health have developed innovative technology to selectively inhibit the part of the immune system responsible for attacking myelin-the insulating material that encases nerve fibers and facilitates electrical communication between brain cells.

18 Nov 2012

New England Biolabs launches new NEBNext Ultra kits at ASHG annual meeting

New England Biolabs, Inc. launched their new NEBNext "Ultra" kits at the recent American Society for Human Genetics annual meeting.

From New England Biolabs 17 Nov 2012

Tregs appears to play an important role in suppressing immune response in advance of sepsis

Following an infection, dysregulation of the immune system can result in a systemic inflammatory response and an often fatal condition called severe sepsis or septic shock. Sepsis is not uncommon, yet its cause and underlying immune dysfunction remain poorly understood.

17 Nov 2012

Researchers identify broad patterns of gene activity that correspond to aggression

With a mate and a nest to protect, the male threespined stickleback is a fierce fish, chasing and biting other males until they go away.

15 Nov 2012

RXi announces pharmacokinetic results from RXI-109 Phase 1 study in healthy subjects

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.

15 Nov 2012

UiO researchers discover enzyme critical for spread of cancer

Enzyme hunters at UiO have discovered the function of an enzyme that is important in the spreading of cancer. Cancer researchers now hope to inhibit the enzyme.

15 Nov 2012

Pig genes resemble human genes when associated with diabetes, obesity

Insights into the genetic code of pigs that reveal how the species evolved could improve the health of animals in future.

15 Nov 2012

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of liver disease associated with AAT deficiency. These data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, "The Liver Meeting") held November 9-13, 2012 in Boston.

15 Nov 2012

Brevetoxin-2 stimulates nerve cell growth and plasticity in cultured mouse neurons

A new study using brevetoxin-2, a compound produced naturally by marine algae, stimulated nerve cell growth and plasticity in cultured mouse neurons. This research advances a potentially new pharmacological treatment to aid recovery of brain function following a stroke or other traumatic brain injury.

14 Nov 2012

Tiltan Pharma initiates enrollment in TL-118 Phase 2 trial for metastatic pancreatic cancer

Tiltan Pharma Ltd. today announced that it has enrolled the first U.S. patient, at White Plains Hospital in Westchester County N.Y., in a Phase 2 clinical trial of its anti-angiogenic product, TL-118, for the treatment of metastatic pancreatic cancer.

14 Nov 2012

Biotechnology News and Research

UMDNJ, Proteonomix commence screening of patients with ESLD for use in UMK-121 clinical trial

Novel technology can lead to more efficient and cheaper therapy for Pompe disease

Emory University, Georgia Tech to establish Malaria Host-Pathogen Interaction Center

Patheon to launch $30 million transferable rights offering

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

HORIBA Europe opens new R&D facility

GVK Biosciences receives AERB approvals to carry out 3H and 14C synthesis activities

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Massimo CEO wins Ernst & Young Entrepreneur Of The Year Award

New nanoparticle halts relapsing remitting multiple sclerosis in mouse model

NIH-funded scientists develop new treatment to combat autoimmune disorders in mouse model

New England Biolabs launches new NEBNext Ultra kits at ASHG annual meeting

Tregs appears to play an important role in suppressing immune response in advance of sepsis

Researchers identify broad patterns of gene activity that correspond to aggression

RXi announces pharmacokinetic results from RXI-109 Phase 1 study in healthy subjects

UiO researchers discover enzyme critical for spread of cancer

Pig genes resemble human genes when associated with diabetes, obesity

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Brevetoxin-2 stimulates nerve cell growth and plasticity in cultured mouse neurons

Tiltan Pharma initiates enrollment in TL-118 Phase 2 trial for metastatic pancreatic cancer

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News